Published in Cell on October 14, 2011
Pushing the limits of targeted therapy in chronic myeloid leukaemia. Nat Rev Cancer (2012) 2.35
Role of ABL family kinases in cancer: from leukaemia to solid tumours. Nat Rev Cancer (2013) 1.92
Structural insights for engineering binding proteins based on non-antibody scaffolds. Curr Opin Struct Biol (2012) 1.18
Mutations of FLT3/ITD confer resistance to multiple tyrosine kinase inhibitors. Leukemia (2012) 1.18
Systems-pharmacology dissection of a drug synergy in imatinib-resistant CML. Nat Chem Biol (2012) 1.10
NMR reveals the allosteric opening and closing of Abelson tyrosine kinase by ATP-site and myristoyl pocket inhibitors. Proc Natl Acad Sci U S A (2013) 1.03
Modular evolution of phosphorylation-based signalling systems. Philos Trans R Soc Lond B Biol Sci (2012) 1.02
Structure and dynamic regulation of Abl kinases. J Biol Chem (2013) 1.01
An evolutionarily conserved synthetic lethal interaction network identifies FEN1 as a broad-spectrum target for anticancer therapeutic development. PLoS Genet (2013) 1.00
Nanobodies and recombinant binders in cell biology. J Cell Biol (2015) 0.96
The growing arsenal of ATP-competitive and allosteric inhibitors of BCR-ABL. Cancer Res (2012) 0.95
Structure, regulation, signaling, and targeting of abl kinases in cancer. Genes Cancer (2012) 0.90
Dissection of the BCR-ABL signaling network using highly specific monobody inhibitors to the SHP2 SH2 domains. Proc Natl Acad Sci U S A (2013) 0.90
Adhiron: a stable and versatile peptide display scaffold for molecular recognition applications. Protein Eng Des Sel (2014) 0.89
Molecular mechanisms of SH2- and PTB-domain-containing proteins in receptor tyrosine kinase signaling. Cold Spring Harb Perspect Biol (2013) 0.89
BCR-ABL1 kinase: hunting an elusive target with new weapons. Chem Biol (2011) 0.89
Delivery of antibody mimics into mammalian cells via anthrax toxin protective antigen. Chembiochem (2014) 0.86
Phosphotyrosine recognition domains: the typical, the atypical and the versatile. Cell Commun Signal (2012) 0.86
The Philadelphia chromosome in leukemogenesis. Chin J Cancer (2016) 0.86
Crk and ABI1: binary molecular switches that regulate abl tyrosine kinase and signaling to the cytoskeleton. Genes Cancer (2012) 0.86
PAPTi: a peptide aptamer interference toolkit for perturbation of protein-protein interaction networks. Sci Rep (2013) 0.84
Identification of protein interactions involved in cellular signaling. Mol Cell Proteomics (2013) 0.84
Intramolecular dynamics within the N-Cap-SH3-SH2 regulatory unit of the c-Abl tyrosine kinase reveal targeting to the cellular membrane. J Biol Chem (2013) 0.82
Two-state dynamics of the SH3-SH2 tandem of Abl kinase and the allosteric role of the N-cap. Proc Natl Acad Sci U S A (2013) 0.81
Combining biophysical methods to analyze the disulfide bond in SH2 domain of C-terminal Src kinase. Biophys Rep (2016) 0.81
Targeting allosteric regulatory modules in oncoproteins: "drugging the undruggable". Oncotarget (2011) 0.80
The SH2 domain regulates c-Abl kinase activation by a cyclin-like mechanism and remodulation of the hinge motion. PLoS Comput Biol (2014) 0.80
Delivery of antibodies to the cytosol: debunking the myths. MAbs (2014) 0.79
Defying c-Abl signaling circuits through small allosteric compounds. Front Genet (2014) 0.79
Allosteric BCR-ABL inhibitors in Philadelphia chromosome-positive acute lymphoblastic leukemia: novel opportunities for drug combinations to overcome resistance. Haematologica (2012) 0.79
Misfolding, Aggregation, and Disordered Segments in c-Abl and p53 in Human Cancer. Front Oncol (2015) 0.79
ETO family protein Mtgr1 mediates Prdm14 functions in stem cell maintenance and primordial germ cell formation. Elife (2015) 0.77
Allosteric Inhibition of Bcr-Abl Kinase by High Affinity Monobody Inhibitors Directed to the Src Homology 2 (SH2)-Kinase Interface. J Biol Chem (2016) 0.76
The other Achilles' heel of BCR-ABL1. Haematologica (2012) 0.75
Monobodies and other synthetic binding proteins for expanding protein science. Protein Sci (2017) 0.75
Therapeutics. Another tool in the BCR-ABL kit? Nat Rev Cancer (2011) 0.75
Directed Evolution of a Highly Specific FN3 Monobody to the SH3 Domain of Human Lyn Tyrosine Kinase. PLoS One (2016) 0.75
Streamlining the Pipeline for Generation of Recombinant Affinity Reagents by Integrating the Affinity Maturation Step. Int J Mol Sci (2015) 0.75
The CCP4 suite: programs for protein crystallography. Acta Crystallogr D Biol Crystallogr (1994) 187.88
MolProbity: all-atom contacts and structure validation for proteins and nucleic acids. Nucleic Acids Res (2007) 37.31
Optimal description of a protein structure in terms of multiple groups undergoing TLS motion. Acta Crystallogr D Biol Crystallogr (2006) 14.21
A graphical user interface to the CCP4 program suite. Acta Crystallogr D Biol Crystallogr (2003) 13.43
Induction of chronic myelogenous leukemia in mice by the P210bcr/abl gene of the Philadelphia chromosome. Science (1990) 10.59
Structural mechanism for STI-571 inhibition of abelson tyrosine kinase. Science (2000) 9.29
Efficient site-directed mutagenesis using uracil-containing DNA. Methods Enzymol (1991) 7.94
The development of imatinib as a therapeutic agent for chronic myeloid leukemia. Blood (2004) 6.92
Six-year follow-up of patients receiving imatinib for the first-line treatment of chronic myeloid leukemia. Leukemia (2009) 6.29
Structural basis for the autoinhibition of c-Abl tyrosine kinase. Cell (2003) 5.44
Mechanisms of BCR-ABL in the pathogenesis of chronic myelogenous leukaemia. Nat Rev Cancer (2005) 4.30
A noncatalytic domain conserved among cytoplasmic protein-tyrosine kinases modifies the kinase function and transforming activity of Fujinami sarcoma virus P130gag-fps. Mol Cell Biol (1986) 4.00
Transient potent BCR-ABL inhibition is sufficient to commit chronic myeloid leukemia cells irreversibly to apoptosis. Cancer Cell (2008) 3.68
A myristoyl/phosphotyrosine switch regulates c-Abl. Cell (2003) 3.48
Targeting Bcr-Abl by combining allosteric with ATP-binding-site inhibitors. Nature (2010) 3.39
Evidence that SH2 domains promote processive phosphorylation by protein-tyrosine kinases. Curr Biol (1995) 3.12
Regulation of the c-Abl and Bcr-Abl tyrosine kinases. Nat Rev Mol Cell Biol (2004) 3.10
SH2 domains, interaction modules and cellular wiring. Trends Cell Biol (2001) 3.01
The BCR-ABL story: bench to bedside and back. Annu Rev Immunol (2004) 3.00
Supercharging proteins can impart unusual resilience. J Am Chem Soc (2007) 2.52
Structural coupling of SH2-kinase domains links Fes and Abl substrate recognition and kinase activation. Cell (2008) 2.46
Chronic myeloid leukemia: mechanisms of blastic transformation. J Clin Invest (2010) 2.44
Critical role for Gab2 in transformation by BCR/ABL. Cancer Cell (2002) 2.42
Flying under the radar: the new wave of BCR-ABL inhibitors. Nat Rev Drug Discov (2007) 2.40
Organization of the SH3-SH2 unit in active and inactive forms of the c-Abl tyrosine kinase. Mol Cell (2006) 2.28
Stat5 is indispensable for the maintenance of bcr/abl-positive leukaemia. EMBO Mol Med (2010) 2.23
Controlling protein association and subcellular localization with a synthetic ligand that induces heterodimerization of proteins. Proc Natl Acad Sci U S A (1996) 2.20
High-affinity single-domain binding proteins with a binary-code interface. Proc Natl Acad Sci U S A (2007) 2.18
A coiled-coil oligomerization domain of Bcr is essential for the transforming function of Bcr-Abl oncoproteins. Mol Cell Biol (1993) 2.18
ProtorP: a protein-protein interaction analysis server. Bioinformatics (2008) 2.09
Solution conformations and dynamics of ABL kinase-inhibitor complexes determined by NMR substantiate the different binding modes of imatinib/nilotinib and dasatinib. J Biol Chem (2008) 2.09
Mechanisms of resistance to STI571 in Philadelphia chromosome-associated leukemias. Oncogene (2003) 1.96
An intramolecular SH3-domain interaction regulates c-Abl activity. Nat Genet (1998) 1.71
Signal transducer and activator of transcription (STAT)5 activation by BCR/ABL is dependent on intact Src homology (SH)3 and SH2 domains of BCR/ABL and is required for leukemogenesis. J Exp Med (1999) 1.61
A potent and highly specific FN3 monobody inhibitor of the Abl SH2 domain. Nat Struct Mol Biol (2010) 1.47
SH2 domains: modulators of nonreceptor tyrosine kinase activity. Curr Opin Struct Biol (2009) 1.45
Monobodies: antibody mimics based on the scaffold of the fibronectin type III domain. Methods Mol Biol (2007) 1.41
The Grb2 binding site is required for the induction of chronic myeloid leukemia-like disease in mice by the Bcr/Abl tyrosine kinase. Blood (2000) 1.20
BCR-ABL SH3-SH2 domain mutations in chronic myeloid leukemia patients on imatinib. Blood (2010) 1.19
The SH2 domain of P210BCR/ABL is not required for the transformation of hematopoietic factor-dependent cells. Blood (1995) 1.15
A remote substrate docking mechanism for the tec family tyrosine kinases. Biochemistry (2007) 1.04
Expression, purification, and crystallization of the RGS-like domain from the Rho nucleotide exchange factor, PDZ-RhoGEF, using the surface entropy reduction approach. Protein Expr Purif (2001) 1.01
Intrinsic differences between the catalytic properties of the oncogenic NUP214-ABL1 and BCR-ABL1 fusion protein kinases. Leukemia (2008) 1.00
Hydrophobic interaction between the SH2 domain and the kinase domain is required for the activation of Csk. J Mol Biol (2010) 0.99
The chemokine interleukin-8 and the surface activation protein CD69 are markers for Bcr-Abl activity in chronic myeloid leukemia. Mol Oncol (2008) 0.89
Functional organization of the yeast proteome by systematic analysis of protein complexes. Nature (2002) 45.19
Systematic identification of protein complexes in Saccharomyces cerevisiae by mass spectrometry. Nature (2002) 37.66
Proteome survey reveals modularity of the yeast cell machinery. Nature (2006) 20.77
Molecular requirements for epithelial-mesenchymal transition during tumor progression. Curr Opin Cell Biol (2005) 11.46
RNAi screen identifies Brd4 as a therapeutic target in acute myeloid leukaemia. Nature (2011) 11.44
Somatic mutations of calreticulin in myeloproliferative neoplasms. N Engl J Med (2013) 9.65
The minimum information required for reporting a molecular interaction experiment (MIMIx). Nat Biotechnol (2007) 8.24
Revised international prognostic scoring system for myelodysplastic syndromes. Blood (2012) 8.12
Beta-catenin and TCF mediate cell positioning in the intestinal epithelium by controlling the expression of EphB/ephrinB. Cell (2002) 8.08
An orthogonal proteomic-genomic screen identifies AIM2 as a cytoplasmic DNA sensor for the inflammasome. Nat Immunol (2009) 7.93
A physical and functional map of the human TNF-alpha/NF-kappa B signal transduction pathway. Nat Cell Biol (2004) 7.23
Systematic discovery of in vivo phosphorylation networks. Cell (2007) 6.94
ELM server: A new resource for investigating short functional sites in modular eukaryotic proteins. Nucleic Acids Res (2003) 6.86
PreBIND and Textomy--mining the biomedical literature for protein-protein interactions using a support vector machine. BMC Bioinformatics (2003) 6.31
A global protein kinase and phosphatase interaction network in yeast. Science (2010) 5.95
New insights into the prognostic impact of the karyotype in MDS and correlation with subtypes: evidence from a core dataset of 2124 patients. Blood (2007) 5.80
DeltaEF1 is a transcriptional repressor of E-cadherin and regulates epithelial plasticity in breast cancer cells. Oncogene (2005) 5.74
Structural basis for the autoinhibition of c-Abl tyrosine kinase. Cell (2003) 5.44
Dynamic modularity in protein interaction networks predicts breast cancer outcome. Nat Biotechnol (2009) 5.41
Dissecting virulence: systematic and functional analyses of a pathogenicity island. Proc Natl Acad Sci U S A (2004) 5.34
An experimentally derived confidence score for binary protein-protein interactions. Nat Methods (2008) 5.27
Peroxisomes are signaling platforms for antiviral innate immunity. Cell (2010) 5.24
Histone recognition and large-scale structural analysis of the human bromodomain family. Cell (2012) 5.15
Ras and TGF[beta] cooperatively regulate epithelial cell plasticity and metastasis: dissection of Ras signaling pathways. J Cell Biol (2002) 5.07
NF-kappaB is essential for epithelial-mesenchymal transition and metastasis in a model of breast cancer progression. J Clin Invest (2004) 5.06
Early lineage segregation between epiblast and primitive endoderm in mouse blastocysts through the Grb2-MAPK pathway. Dev Cell (2006) 4.77
Reading protein modifications with interaction domains. Nat Rev Mol Cell Biol (2006) 4.55
Diverse cellular and molecular mechanisms contribute to epithelial plasticity and metastasis. Nat Rev Mol Cell Biol (2003) 4.53
The Hippo pathway regulates Wnt/beta-catenin signaling. Dev Cell (2010) 4.49
The CRAPome: a contaminant repository for affinity purification-mass spectrometry data. Nat Methods (2013) 4.34
Human Proteinpedia enables sharing of human protein data. Nat Biotechnol (2008) 4.21
IFIT1 is an antiviral protein that recognizes 5'-triphosphate RNA. Nat Immunol (2011) 4.18
Nck adaptor proteins link nephrin to the actin cytoskeleton of kidney podocytes. Nature (2006) 4.05
Mast Cells, Mastocytosis, and Related Disorders. N Engl J Med (2015) 3.90
Cell signaling in space and time: where proteins come together and when they're apart. Science (2009) 3.88
New comprehensive cytogenetic scoring system for primary myelodysplastic syndromes (MDS) and oligoblastic acute myeloid leukemia after MDS derived from an international database merge. J Clin Oncol (2012) 3.88
Linear motif atlas for phosphorylation-dependent signaling. Sci Signal (2008) 3.77
Chemical proteomic profiles of the BCR-ABL inhibitors imatinib, nilotinib, and dasatinib reveal novel kinase and nonkinase targets. Blood (2007) 3.59
A myristoyl/phosphotyrosine switch regulates c-Abl. Cell (2003) 3.48
Proteomic, functional, and domain-based analysis of in vivo 14-3-3 binding proteins involved in cytoskeletal regulation and cellular organization. Curr Biol (2004) 3.45
The Nedd4 family of E3 ubiquitin ligases: functional diversity within a common modular architecture. Oncogene (2004) 3.44
Par6-aPKC uncouples ErbB2 induced disruption of polarized epithelial organization from proliferation control. Nat Cell Biol (2006) 3.42
An efficient tandem affinity purification procedure for interaction proteomics in mammalian cells. Nat Methods (2006) 3.38
A Rich1/Amot complex regulates the Cdc42 GTPase and apical-polarity proteins in epithelial cells. Cell (2006) 3.38
Cytokine signaling and hematopoietic homeostasis are disrupted in Lnk-deficient mice. J Exp Med (2002) 3.24
Target profiling of small molecules by chemical proteomics. Nat Chem Biol (2009) 3.20
p38alpha suppresses normal and cancer cell proliferation by antagonizing the JNK-c-Jun pathway. Nat Genet (2007) 3.19
Protein phosphorylation in signaling--50 years and counting. Trends Biochem Sci (2005) 3.19
A polarity complex of mPar-6 and atypical PKC binds, phosphorylates and regulates mammalian Lgl. Nat Cell Biol (2003) 3.11
Regulation of the c-Abl and Bcr-Abl tyrosine kinases. Nat Rev Mol Cell Biol (2004) 3.10
Structure-based assembly of protein complexes in yeast. Science (2004) 2.89
High-throughput generation of synthetic antibodies from highly functional minimalist phage-displayed libraries. J Mol Biol (2007) 2.88
EphB receptor activity suppresses colorectal cancer progression. Nature (2005) 2.84
Cancer stem cell definitions and terminology: the devil is in the details. Nat Rev Cancer (2012) 2.76
NetworKIN: a resource for exploring cellular phosphorylation networks. Nucleic Acids Res (2007) 2.69
Autocrine PDGFR signaling promotes mammary cancer metastasis. J Clin Invest (2006) 2.68
Expression profiling of epithelial plasticity in tumor progression. Oncogene (2003) 2.67
Complement factor H binds malondialdehyde epitopes and protects from oxidative stress. Nature (2011) 2.64
A chemical and phosphoproteomic characterization of dasatinib action in lung cancer. Nat Chem Biol (2010) 2.53
The Btk tyrosine kinase is a major target of the Bcr-Abl inhibitor dasatinib. Proc Natl Acad Sci U S A (2007) 2.51
Identification and characterization of NleA, a non-LEE-encoded type III translocated virulence factor of enterohaemorrhagic Escherichia coli O157:H7. Mol Microbiol (2004) 2.51
The human and mouse complement of SH2 domain proteins-establishing the boundaries of phosphotyrosine signaling. Mol Cell (2006) 2.51
Structural coupling of SH2-kinase domains links Fes and Abl substrate recognition and kinase activation. Cell (2008) 2.46
Molecular aspects of epithelial cell plasticity: implications for local tumor invasion and metastasis. Mutat Res (2004) 2.45
Rediscovering the sweet spot in drug discovery. Drug Discov Today (2003) 2.45
Nonsense-mediated decay microarray analysis identifies mutations of EPHB2 in human prostate cancer. Nat Genet (2004) 2.44
NSs protein of rift valley fever virus induces the specific degradation of the double-stranded RNA-dependent protein kinase. J Virol (2009) 2.39
Clarifying the role of Stat5 in lymphoid development and Abelson-induced transformation. Blood (2006) 2.38
Crystal structure of full-length KcsA in its closed conformation. Proc Natl Acad Sci U S A (2009) 2.35
Transgenic RNA interference in ES cell-derived embryos recapitulates a genetic null phenotype. Nat Biotechnol (2003) 2.34
Temporal regulation of EGF signalling networks by the scaffold protein Shc1. Nature (2013) 2.33
Hepatocytes convert to a fibroblastoid phenotype through the cooperation of TGF-beta1 and Ha-Ras: steps towards invasiveness. J Cell Sci (2002) 2.32
ILEI: a cytokine essential for EMT, tumor formation, and late events in metastasis in epithelial cells. Cancer Cell (2006) 2.30
Progressive peripheral arterial occlusive disease and other vascular events during nilotinib therapy in CML. Am J Hematol (2011) 2.29
Positive selection of tyrosine loss in metazoan evolution. Science (2009) 2.28
Organization of the SH3-SH2 unit in active and inactive forms of the c-Abl tyrosine kinase. Mol Cell (2006) 2.28
Stat5 tetramer formation is associated with leukemogenesis. Cancer Cell (2005) 2.26
Stat5 is indispensable for the maintenance of bcr/abl-positive leukaemia. EMBO Mol Med (2010) 2.23
Post-translational modifications in signal integration. Nat Struct Mol Biol (2010) 2.23
ProHits: integrated software for mass spectrometry-based interaction proteomics. Nat Biotechnol (2010) 2.22
Molecular mechanism of Thioflavin-T binding to amyloid fibrils. Biochim Biophys Acta (2010) 2.22
Adipose vascular endothelial growth factor regulates metabolic homeostasis through angiogenesis. Cell Metab (2013) 2.21
Persistent STAT3 activation in colon cancer is associated with enhanced cell proliferation and tumor growth. Neoplasia (2005) 2.18
High-affinity single-domain binding proteins with a binary-code interface. Proc Natl Acad Sci U S A (2007) 2.18
Podocyte-specific loss of Cdc42 leads to congenital nephropathy. J Am Soc Nephrol (2012) 2.16